Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Clinical-stage biotechnology company developing dry powder inhalation therapies for respiratory, CNS, fibrotic diseases.
Chance Pharmaceuticals is a clinical-stage biotechnology company based in Hangzhou, China, that develops dry powder inhalation therapies for chronic respiratory diseases, central nervous system disorders, and fibrotic conditions. The enterprise utilizes proprietary spray drying and milling platforms to formulate efficient inhalation treatments, operating dedicated research and production facilities that are fully compliant with FDA and EMA manufacturing standards. The company's primary pipeline asset is CXG87, an improved budesonide and formoterol formulation currently advancing through Phase III clinical trials. To support its ongoing clinical development and future market entry, the firm secured an exclusive commercialization agreement with Huadong Medicine. The organization has raised $30 million in Series C financing, alongside a recent funding round led by Heda Health Fund and Qihang Venture Capital. Chance Pharmaceuticals was founded in 2015 by chief executive officer Donghao Chen.
Chance Pharmaceuticals has raised $30.0M across 1 funding round.
Chance Pharmaceuticals has raised $30.0M in total across 1 funding round.
Chance Pharmaceuticals has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series C in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 12, 2021 | $30M Series C | Zhihua YU | Guozhong Capital, HEDA BioVenture | Announced |
Chance Pharmaceuticals has raised $30.0M in total across 1 funding round.
Chance Pharmaceuticals's investors include Zhihua Yu, Guozhong Capital, HEDA BioVenture.